Farxiga vs Ozempic
Side-by-side cost comparison based on Medicare Part D data
Farxiga
Dapagliflozin
Manufactured by AstraZeneca
Ozempic
Semaglutide
Manufactured by Novo Nordisk
Farxiga costs 61% less per claim than Ozempic ($266.00 vs $685.00). A generic version of Farxiga is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Farxiga | Ozempic |
|---|---|---|
| Avg Cost Per Claim | $266.00 | $685.00 |
| Total Medicare Spending | $3.0B | $5.0B |
| Total Beneficiaries | 1,340,000 | 1,180,000 |
| Total Claims | 11,240,000 | 7,240,000 |
| Annual Cost/Patient | $2,229.00 | $4,200.00 |
| Year-over-Year Change | +31.5% | +72.5% |
| Generic Available | Yes | No |
| Patent Expiration | Nov 13, 2025 | Sep 20, 2031 |
| Manufacturer | AstraZeneca | Novo Nordisk |
| Condition | Diabetes | Diabetes |
| Generic Name | Dapagliflozin | Semaglutide |
Farxiga vs Ozempic: What the Data Shows
Farxiga (Dapagliflozin) and Ozempic (Semaglutide) are both used to treat diabetes. Based on Medicare Part D data, Farxiga costs $266.00 per claim, which is 61% less than Ozempic at $685.00 per claim.
Medicare spent $3.0B on Farxiga and $5.0B on Ozempic. In terms of patient reach, Farxiga serves more beneficiaries (1,340,000 vs 1,180,000).
Year-over-year spending changed +31.5% for Farxiga and +72.5% for Ozempic. Farxiga saw significant spending growth, suggesting increased utilization or price increases. Ozempic saw significant spending growth, suggesting increased utilization or price increases.
Farxiga has a generic available, while Ozempic remains brand-only until its patent expires Sep 20, 2031.
Frequently Asked Questions
Farxiga is cheaper at $266.00 per claim, compared to $685.00 for Ozempic. That makes Farxiga about 61% less expensive per claim based on Medicare Part D data.
Yes, both Farxiga and Ozempic are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Farxiga has a generic version (Dapagliflozin) available, which is typically much cheaper. Ozempic is currently brand-only, with patent expiring Sep 20, 2031.
Medicare Part D spent $3.0B on Farxiga covering 1,340,000 beneficiaries, and $5.0B on Ozempic covering 1,180,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.